Telomir Pharmaceuticals
CompanyUnited States
Telomir Pharmaceuticals develops 2 assets, the furthest in phase 1 (Telomir-Zn in TNBC). Mostly small molecule acting on telomerase and telomere maintenance; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 1
- Raised
- US$17.8m
- 0
- Trials
- 4
- Signals
Pipeline
2Chelates intracellular iron, reducing iron-dependent KDM activity to promote epigenetic reprogramming and reactivate silenced tumor-suppressor genes.
Phase 1, Small molecule, Telomerase and telomere maintenance, TNBC, triple-negative breast cancer (Preclinical)
Oral small molecule metal-ion regulator regulating telomerase and metal ion homeostasis
Preclinical, Small molecule, Telomerase and telomere maintenance
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Funding rounds and grants4
- Deals4
- People10
- Signals4
- Similar companies6